Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490532 | 0.86 | SRC (0.56) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL31173724 | 0.86 | SRC (0.56) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL20804355 | 0.84 | HPGD (0.57) | SRCRAB9AMAPK1TP53ALDH1A1 | |
| SCHEMBL3109722 | 0.84 | SRC (0.61) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL29699631 | 0.84 | SRC (0.61) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL5338226 | 0.83 | HPGD (0.63) | EPHX2TP53ALDH1A1LMNAHPGD | |
| SCHEMBL18722262 | 0.82 | SRC (0.56) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL885310 | 0.82 | SRC (0.56) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL30006359 | 0.82 | SRC (0.56) | SRCRAB9AMAPK1ANPEPPOLB | |
| SCHEMBL5315407 | 0.82 | SRC (0.56) | SRCRAB9AMAPK1ANPEPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | SRC 3665/4885RAB9A 1714/4885MAPK1 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.